Gamida Cell

NASDAQ:GMDA

Jerusalem, Israel· Est. 2000

Gamida Cell pioneers nicotinamide-enhanced allogeneic cell therapies for hematologic conditions, with two FDA-approved products for transplantation and stem cell mobilization.

gamida-cell.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

AI Company Overview

Gamida Cell pioneers nicotinamide-enhanced allogeneic cell therapies for hematologic conditions, with two FDA-approved products for transplantation and stem cell mobilization.

OncologyHematology

Technology Platform

Proprietary nicotinamide (NAM) ex vivo cell culture technology that enhances and expands hematopoietic stem cells while improving their homing, retention, and metabolic fitness for transplantation.

Opportunities

Expansion of APHEXDA into sickle cell disease mobilization for gene therapy represents a significant near-term opportunity, while the NAM platform could be leveraged to develop additional enhanced cell therapies for other hematologic conditions.

Risk Factors

Key risks include commercial execution challenges for newly launched cell therapies, high costs and reimbursement hurdles, manufacturing complexity, and competition in stem cell mobilization and transplantation markets.

Competitive Landscape

Competes with traditional cord blood transplants, plerixafor in stem cell mobilization, and other cell therapy approaches; differentiates through NAM-enhanced cell functionality and two complementary approved products addressing different points in the transplantation continuum.

More companies in Israel →